JP2023545424A5 - - Google Patents
Info
- Publication number
- JP2023545424A5 JP2023545424A5 JP2023521545A JP2023521545A JP2023545424A5 JP 2023545424 A5 JP2023545424 A5 JP 2023545424A5 JP 2023521545 A JP2023521545 A JP 2023521545A JP 2023521545 A JP2023521545 A JP 2023521545A JP 2023545424 A5 JP2023545424 A5 JP 2023545424A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- aav
- pharmaceutical composition
- poloxamer
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063088886P | 2020-10-07 | 2020-10-07 | |
| US63/088,886 | 2020-10-07 | ||
| US202163147584P | 2021-02-09 | 2021-02-09 | |
| US63/147,584 | 2021-02-09 | ||
| PCT/US2021/053818 WO2022076595A1 (en) | 2020-10-07 | 2021-10-06 | Formulations for suprachoroidal administration such as gel formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023545424A JP2023545424A (ja) | 2023-10-30 |
| JP2023545424A5 true JP2023545424A5 (https=) | 2024-10-24 |
Family
ID=78483535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023521545A Pending JP2023545424A (ja) | 2020-10-07 | 2021-10-06 | ゲル製剤などの脈絡膜上投与用製剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230414788A1 (https=) |
| EP (1) | EP4225380A1 (https=) |
| JP (1) | JP2023545424A (https=) |
| KR (1) | KR20230106598A (https=) |
| AU (1) | AU2021356645A1 (https=) |
| CA (1) | CA3194861A1 (https=) |
| IL (1) | IL301947A (https=) |
| MX (1) | MX2023004005A (https=) |
| TW (1) | TW202228646A (https=) |
| WO (1) | WO2022076595A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3727468A4 (en) | 2017-12-19 | 2021-09-22 | Akouos, Inc. | AAV-MEDIATED THERAPEUTIC ANTIBODIES DELIVERY TO THE INTERNAL EAR |
| EP3886946A1 (en) | 2019-06-05 | 2021-10-06 | Regeneron Pharmaceuticals, Inc. | Devices and methods for precision dose delivery |
| IL303317A (en) | 2020-12-01 | 2023-07-01 | Akouos Inc | ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA |
| US20240307553A1 (en) * | 2021-04-01 | 2024-09-19 | Pfizer Inc. | Pharmaceutical compositions containing adeno-associated viral vector |
| TW202345913A (zh) * | 2022-04-06 | 2023-12-01 | 美商銳進科斯生物股份有限公司 | 用於脈絡膜上投與之調配物諸如凝膠調配物 |
| IL319873A (en) | 2022-09-30 | 2025-05-01 | Regenxbio Inc | Treatment of eye diseases with recombinant viral vectors containing anti-VEGF FAB |
| CN116350801A (zh) * | 2022-11-22 | 2023-06-30 | 四川至善唯新生物科技有限公司 | 一种重组腺相关病毒载体的药物组合物及其用途 |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| WO2024238867A1 (en) | 2023-05-16 | 2024-11-21 | Regenxbio Inc. | Vectorized anti-complement antibodies and administration thereof |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2379166C (en) | 1999-08-09 | 2013-03-26 | Targeted Genetics Corporation | Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs |
| MX359371B (es) | 2001-11-13 | 2018-09-25 | Univ Pennsylvania | Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo. |
| PT1453547T (pt) | 2001-12-17 | 2016-12-28 | Univ Pennsylvania | Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas |
| EP2345731B1 (en) | 2003-09-30 | 2015-10-21 | The Trustees of the University of Pennsylvania | Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof |
| WO2006042252A2 (en) * | 2004-10-08 | 2006-04-20 | Potentia Pharmeceuticals, Inc. | Viral complement control proteins for eye disorders |
| ES2525067T3 (es) | 2005-04-07 | 2014-12-17 | The Trustees Of The University Of Pennsylvania | Método de incremento de la función de un vector de AAV |
| JP4495210B2 (ja) | 2005-06-09 | 2010-06-30 | パナソニック株式会社 | 振幅誤差補償装置及び直交度誤差補償装置 |
| US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
| US8628966B2 (en) | 2010-04-30 | 2014-01-14 | City Of Hope | CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer |
| US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
| WO2012057363A1 (ja) | 2010-10-27 | 2012-05-03 | 学校法人自治医科大学 | 神経系細胞への遺伝子導入のためのアデノ随伴ウイルスビリオン |
| WO2012109570A1 (en) | 2011-02-10 | 2012-08-16 | The University Of North Carolina At Chapel Hill | Viral vectors with modified transduction profiles and methods of making and using the same |
| CN105755044A (zh) | 2011-04-22 | 2016-07-13 | 加利福尼亚大学董事会 | 具有变异衣壳的腺相关病毒病毒体及其使用方法 |
| ES2857773T5 (es) | 2011-08-24 | 2024-06-04 | Univ Leland Stanford Junior | Nuevas proteínas de la cápside de AAV para la transferencia de ácidos nucleicos |
| WO2013170078A1 (en) | 2012-05-09 | 2013-11-14 | Oregon Health & Science University | Adeno associated virus plasmids and vectors |
| CA2905952A1 (en) | 2013-03-13 | 2014-10-02 | The Children's Hospital Of Philadelphia | Adeno-associated virus vectors and methods of use thereof |
| US20140378401A1 (en) * | 2013-06-21 | 2014-12-25 | Gnt, Llc | Ophthalmic Lipophilic and Hydrophilic Drug Delivery Vehicle Formulations |
| ES2739288T3 (es) | 2013-09-13 | 2020-01-30 | California Inst Of Techn | Recuperación selectiva |
| CN106232618A (zh) | 2013-10-11 | 2016-12-14 | 马萨诸塞眼科耳科诊所 | 预测祖先病毒序列的方法及其用途 |
| CA2933900A1 (en) * | 2013-12-20 | 2015-06-25 | Georgia Tech Research Corporation | Formulations and methods for targeted ocular delivery of therapeutic agents |
| WO2015164757A1 (en) | 2014-04-25 | 2015-10-29 | Oregon Health & Science University | Methods of viral neutralizing antibody epitope mapping |
| CN107249522B (zh) | 2014-09-19 | 2021-04-20 | 奥叙拉尔有限公司 | 眼科递送装置 |
| EP3028721A1 (en) * | 2014-12-05 | 2016-06-08 | Exchange Imaging Technologies GmbH | Nanoparticle formulation having reverse-thermal gelation properties for injection |
| CN105147595B (zh) * | 2015-08-18 | 2018-08-31 | 吉林大学 | 吡嘧司特钾温度敏感性水凝胶及其制备方法 |
| KR20240005973A (ko) | 2016-04-15 | 2024-01-12 | 리젠엑스바이오 인크. | 완전히-인간형의 번역후 변형된 항-VEGF Fab를 이용한 눈 질환의 치료 |
| CN107854424A (zh) * | 2017-10-30 | 2018-03-30 | 沈小玲 | 一种阿奇霉素眼用原位凝胶及其制备方法 |
| US10912883B2 (en) | 2017-11-04 | 2021-02-09 | Altaviz, Llc | Gas-powered fluid injection system |
| WO2019173334A1 (en) * | 2018-03-05 | 2019-09-12 | The Schepens Eye Research Institute, Inc. | Engineered vegf variants for retinal neuroprotection, promotion of axon growth and axon regeneration |
| CN111494305A (zh) * | 2020-05-25 | 2020-08-07 | 海宁凤鸣叶绿素有限公司 | 一种叶黄素脂质体眼用温敏型原位凝胶制剂及其制备方法 |
-
2021
- 2021-10-06 KR KR1020237014819A patent/KR20230106598A/ko active Pending
- 2021-10-06 AU AU2021356645A patent/AU2021356645A1/en active Pending
- 2021-10-06 IL IL301947A patent/IL301947A/en unknown
- 2021-10-06 WO PCT/US2021/053818 patent/WO2022076595A1/en not_active Ceased
- 2021-10-06 CA CA3194861A patent/CA3194861A1/en active Pending
- 2021-10-06 JP JP2023521545A patent/JP2023545424A/ja active Pending
- 2021-10-06 EP EP21801750.7A patent/EP4225380A1/en active Pending
- 2021-10-06 MX MX2023004005A patent/MX2023004005A/es unknown
- 2021-10-06 TW TW110137247A patent/TW202228646A/zh unknown
- 2021-10-06 US US18/030,616 patent/US20230414788A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023545424A5 (https=) | ||
| AU2025271096A1 (en) | A modified mGluR6 promoter and methods of use | |
| ES2599632T3 (es) | Composiciones de vectores rAAV que tienen proteínas de la cápside modificadas en tirosina y métodos para su uso | |
| JP7707066B2 (ja) | 体液性免疫を回避する組成物および方法 | |
| JP2024016207A5 (https=) | ||
| WO2020219868A1 (en) | Fully-human post-translationally modified antibody therapeutics | |
| US20230381341A1 (en) | Adeno-associated viruses for ocular delivery of gene therapy | |
| JP2022529775A5 (https=) | ||
| JP2018508519A5 (https=) | ||
| CA2941640A1 (en) | Improved raav vectors and methods for transduction of photoreceptors and rpe cells | |
| US20230265455A1 (en) | Improved aav-mediated x-linked retinoschisis therapies | |
| JP2022523679A5 (https=) | ||
| JP2025503637A5 (https=) | ||
| JP2022539156A (ja) | ヒアルロン酸を用いた眼組織へのａａｖ媒介形質導入の増強 | |
| KR20210153069A (ko) | 섬유아세포 성장 인자 23 관련 저인산혈증성 질환의 유전자 요법 | |
| KR20240116840A (ko) | 변형된 aav 캡시드 단백질 및 이의 용도 | |
| CN119403823A (zh) | 具有增强的肌肉转导效率的肽修饰的aav衣壳 | |
| US20230175015A1 (en) | Immunosuppressive agents and viral delivery re-dosing methods for gene therapy | |
| EP4236999A1 (en) | Vectorized anti-tnf-alfa antibodies for ocular indications | |
| JP2023547832A5 (https=) | ||
| US20240092885A1 (en) | Vector constructs for delivery of nucleic acids encoding therapeutic anti-tnf antibodies and methods of using the same | |
| WO2022130014A1 (en) | Adeno associated viral vector delivery of antibodies for the treatment of disease mediated by dysregulated plasma kallikrein | |
| US10946094B2 (en) | Adenoassociated viral mediated persistant anti-VEGF therapy for ovarian cancer | |
| US12274757B2 (en) | Recombinant adeno-associated viruses encoding serpin peptides and uses thereof | |
| EP4410988A1 (en) | An aav2-vector variant for targeted transfer of genes |